Program
paliroden
Also written as “SR57667B”, “CIL001 (Paliroden)” and “paliroden (CIL001)”.
Its studies are mostly in Parkinson Disease · Alzheimer Disease · Diabetes Mellitus · Tinnitus, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 40 open or running | phase 2since Sep 16, 2005 | Sep 16, 2005 | none ahead |
| Cilcare SAS | 22 open or running | phase 2since Feb 24, 2026 | Feb 24, 2026 | Dec 2027phase 2 · NCT07472907 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 16, 2005First studies: 2 phase 2 studies in Parkinson DiseaseNew to SanofiSanofi · NCT00220272, NCT00228150
- Jan 31, 20062 phase 2 studies in Alzheimer DiseaseSanofi · NCT00285077, NCT00285025
- Feb 24, 2026Cilcare SAS's first study: phase 2 study in Hearing Loss, HiddenNew to Cilcare SASCilcare SAS · NCT07472907 · 135 planned
- Sep 4, 2026Phase 2 study in TinnitusCilcare SAS · NCT07826507 · 60 planned
Ahead
- Dec 2027Primary completion: phase 2 study in Hearing Loss, HiddenCilcare SAS · NCT07472907
- Jan 2028Primary completion: phase 2 study in TinnitusCilcare SAS · NCT07826507
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07826507Tinnitus | 2 | Not yet recruiting | Cilcare SAS | Jan 2028 | 60 |
| NCT07472907Hearing Loss, Hidden | 2 | Not yet recruiting | Cilcare SAS | Dec 2027 | 135 |
| NCT00285077Alzheimer Disease · Canada, Denmark, Finland and more | 2 | Completed | Sanofi | Nov 2006 | 390 |
| NCT00285025Alzheimer Disease | 2 | Completed | Sanofi | 500 | |
| NCT00228150Parkinson Disease · Austria, Canada, Denmark and more | 2 | Completed | Sanofi | Apr 2006 | 564 |
| NCT00220272Parkinson Disease · Canada, Finland, France and more | 2 | Completed | Sanofi | Mar 2007 | 183 |
How it is read
Names in the registry
- “SR57667B”, 4 entries
- “CIL001 (Paliroden)”, 1 entry
- “paliroden (CIL001)”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 2 studies
- Alzheimer Disease, 2 studies
- Diabetes Mellitus, 1 study
- Tinnitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.